Company: ACBM
Filing Date: 2025-07-24
Form Type: 10-K
Source: 0001640334-25-001300
Chunk: 147

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-24
Form: 10-K
Item: Item 15
Chunk 147
---
 carry forward $6,871,829  $6,863,858 Valuation allowance  (6,871,829)  (6,863,858)Deferred tax asset $-  $-  The Company has approximately $33 million net operating loss carryforwards that are available to reduce future taxable income. In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers projected future taxable income and tax planning strategies in making this assessment. Based on the assessment, management has established a full valuation allowance against all of the deferred tax assets for the year ended December 31, 2024 and 2023 because it is more likely than not that all of the deferred tax assets will not be realized.

 F-12Table of Contents

NOTE 6 - RELATED PARTY TRANSACTIONS At December 31, 2024 and 2023, the Company owed $1,100 to its chief executive officer for non-interest-bearing advances made to or expenses paid on behalf of the Company. These advances are due on demand. During the years ended December 31, 2024 and 2023, a minority stockholder advanced $1,000 and $0, and paid expenses of $35,792 and $9,970 on behalf of the Company, all of which was outstanding on December 31, 2024. At December 31, 2024 and 2023, the Company owed $124,488 and $87,696 to the minority stockholder referred to in the preceding paragraph for non-interest-bearing advances made to or expenses paid on behalf of the Company, respectively. These advances are due on demand. The Company has imputed interest at the rate of 4% on the advances made to or expenses paid on behalf of the Company. Imputed interest amounted to $4,339 and $3,206, during the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024 and 2023, the Company had amounts due to related parties of $125,588 and $88,796, respectively.

NOTE 7 – LEASES On November 3, 2021, the Company